ACIU Stock Forecast: AC Immune SA Price Predictions for 2026-2027
The median 12-month analyst price target for AC Immune SA is $8.27. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 66 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores AC Immune SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ACIU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ACIU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | BTIG | Reiterates | Buy | $8.00 |
| 20 Aug 2026 | BTIG | Reiterates | Buy | $8.00 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $8.00 |
| 4 May 2026 | BTIG | Reiterates | Buy | $8.00 |
| 16 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Nov 2025 | BTIG | Reiterates | Buy | — |
| 8 Sept 2025 | BTIG | Reiterates | Buy | — |
| 1 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright& Co. | Reiterates | Buy | — |
| 14 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | BTIG | Initiates | Buy | — |
| 15 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACIU.
This page is one stock. Monday covers all of them.
ACIU appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ACIU vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, AC Immune SA returned −33.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ACIU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 10.7×
- Price / book
- 4.4×
- EV / EBITDA
- —
Cheaper than 11% of US stocks
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −80.7%
- Return on assets
- −15.2%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AC Immune SA has a market value of $211.8M and an enterprise value of $87.0M.
Revenue in the twelve months to 30 June 2026: $17.5M. The latest quarter grew 1057.2% year on year.
Net income over the same four quarters: −$43.2M, a −246.5% net margin.
forward P/E: 3.1× — the forward figure prices analyst consensus estimates, not reported earnings.
AC Immune SA employs 90 people — $195K of revenue per employee.
Data provided by Twelve Data
ACIU and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ACIU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own AC Immune SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ACIU
What is the ACIU stock price forecast for 2026-2027?
The median 12-month analyst price target for AC Immune SA is $8.27, with estimates ranging from $5.42 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACIU stock a buy right now?
Of the 4 analysts covering AC Immune SA, 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AC Immune SA 66 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACIU?
As at 21 Nov 2026, AC Immune SA ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will ACIU stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $8.27, and Ticker Nerd's factor model ranks AC Immune SA 66 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACIU stock forecast for 2030?
No analyst covering AC Immune SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACIU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.42 to $12 over the next 12 months.
How has ACIU stock performed over the past year?
AC Immune SA returned -33.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AC Immune SA do?
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases associated with misfolded proteins. Its research and development activities address conditions including Alzheimer’s disease, Parkinson’s disease, and selected neuro-orphan disorders.
About AC Immune SA.
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases associated with misfolded proteins. Its research and development activities address conditions including Alzheimer’s disease, Parkinson’s disease, and selected neuro-orphan disorders. The company uses its proprietary SupraAntigen and Morphomer platforms to discover and design therapeutic and diagnostic products, including antibodies, small molecules, vaccines, and imaging agents. These technologies are intended to selectively target disease-related proteins such as amyloid, tau, and alpha-synuclein, supporting applications in disease prevention, diagnosis, monitoring, and treatment. AC Immune SA operates across the biotechnology and pharmaceutical sectors, combining molecular research, clinical development, biomarker discovery, and diagnostic innovation. Its work contributes to the development of disease-modifying approaches in areas where protein aggregation plays a central role, while its partnerships and product programs connect the company with global pharmaceutical, healthcare, and clinical research markets. Headquartered in Lausanne, Switzerland, AC Immune SA represents a specialized participant in the biopharmaceutical market for neurodegenerative disease.
CEO Dr. Martin Zugel M.D., Ph.D. · 90 employees · Switzerland · https://www.acimmune.com